Results

1–10 of 244 results for Anti-VEGF

Prophylactic Intraocular Pressure–Lowering Measures in Antivascular Endothelial Growth Factor Therapy: Systematic Review and Meta-Analysis
Parnian Arjmand, MD, MSc, FRCSC, DABO
Annual Meeting Talks
2022
National vs International Outcomes and Practice Patterns of Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity
Nimesh A. Patel, MD
Annual Meeting Talks
2022
Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases
Matthew Starr, MD
Annual Meeting Talks
2022
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MEfRVO) Comparing Ozurdex vs Anti-VEGF Therapy
John J. Huang, MD
Annual Meeting Talks
2022
Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials
Dilsher S. Dhoot, MD
Annual Meeting Talks
2022
Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database
Anita Barikian, MD
Annual Meeting Talks
2022
Prospective Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: One-Year Outcomes
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2022